348 related articles for article (PubMed ID: 20444845)
1. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
Eidtmann H; de Boer R; Bundred N; Llombart-Cussac A; Davidson N; Neven P; von Minckwitz G; Miller J; Schenk N; Coleman R
Ann Oncol; 2010 Nov; 21(11):2188-2194. PubMed ID: 20444845
[TBL] [Abstract][Full Text] [Related]
2. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Coleman R; de Boer R; Eidtmann H; Llombart A; Davidson N; Neven P; von Minckwitz G; Sleeboom HP; Forbes J; Barrios C; Frassoldati A; Campbell I; Paija O; Martin N; Modi A; Bundred N
Ann Oncol; 2013 Feb; 24(2):398-405. PubMed ID: 23047045
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results.
Takahashi S; Iwase T; Kohno N; Ishikawa T; Taguchi T; Takahashi M; Horiguchi J; Nakamura S; Hozumi Y; Fukunaga M; Noguchi S
Breast Cancer Res Treat; 2012 Jun; 133(2):685-93. PubMed ID: 22307266
[TBL] [Abstract][Full Text] [Related]
5. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Safra T; Bernstein-Molho R; Greenberg J; Pelles-Avraham S; Stephansky I; Sarid D; Inbar MJ; Stemmer SM; Geffen DB
Oncology; 2011; 81(5-6):298-305. PubMed ID: 22156381
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
7. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Brufsky AM; Harker WG; Beck JT; Bosserman L; Vogel C; Seidler C; Jin L; Warsi G; Argonza-Aviles E; Hohneker J; Ericson SG; Perez EA
Cancer; 2012 Mar; 118(5):1192-201. PubMed ID: 21987386
[TBL] [Abstract][Full Text] [Related]
8. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
Logman JFS; Heeg BMS; Botteman MF; Kaura S; van Hout BA
Ann Oncol; 2010 Jul; 21(7):1529-1536. PubMed ID: 19955334
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
[TBL] [Abstract][Full Text] [Related]
11. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Bundred NJ; Campbell ID; Davidson N; DeBoer RH; Eidtmann H; Monnier A; Neven P; von Minckwitz G; Miller JC; Schenk NL; Coleman RE
Cancer; 2008 Mar; 112(5):1001-10. PubMed ID: 18205185
[TBL] [Abstract][Full Text] [Related]
12. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.
Nuzzo F; Gallo C; Lastoria S; Di Maio M; Piccirillo MC; Gravina A; Landi G; Rossi E; Pacilio C; Labonia V; Di Rella F; Bartiromo A; Buonfanti G; De Feo G; Esposito G; D'Aniello R; Maiolino P; Signoriello S; De Maio E; Tinessa V; Colantuoni G; De Laurentiis M; D'Aiuto M; Di Bonito M; Botti G; Giordano P; Daniele G; Morabito A; Normanno N; de Matteis A; Perrone F
Ann Oncol; 2012 Aug; 23(8):2027-2033. PubMed ID: 22412041
[TBL] [Abstract][Full Text] [Related]
13. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Wagner-Johnston ND; Sloan JA; Liu H; Kearns AE; Hines SL; Puttabasavaiah S; Dakhil SR; Lafky JM; Perez EA; Loprinzi CL
Cancer; 2015 Aug; 121(15):2537-43. PubMed ID: 25930719
[TBL] [Abstract][Full Text] [Related]
14. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
[TBL] [Abstract][Full Text] [Related]
15. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
[TBL] [Abstract][Full Text] [Related]
18. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.
Rossi E; Morabito A; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; De Maio E; Di Maio M; Piccirillo MC; De Feo G; D'Aiuto G; Botti G; Chiodini P; Gallo C; Perrone F; de Matteis A
J Clin Oncol; 2009 Jul; 27(19):3192-7. PubMed ID: 19380451
[TBL] [Abstract][Full Text] [Related]
19. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
Brufsky AM
Clin Breast Cancer; 2007 Dec; 8 Suppl 1():S22-34. PubMed ID: 18282367
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Brufsky A; Harker WG; Beck JT; Carroll R; Tan-Chiu E; Seidler C; Hohneker J; Lacerna L; Petrone S; Perez EA
J Clin Oncol; 2007 Mar; 25(7):829-36. PubMed ID: 17159193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
